PHAT 241018 20.00C (PHAT241018C20000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PHAT241018C20000

Watchlist

0.55
+0.15+37.50%

15min DelayClose Oct 3 16:00 ET

0.75High0.45Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga16:31 ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
PR NewswireSep 25 19:15 ET
Trending Stocks Today | Smith Micro Software Surges 61.22% Post-Market
Moomoo NewsSep 16 18:05 ET
Buy Rating for Phathom Pharmaceuticals Amid Strong Voquezna Prescription Growth
TipRanksSep 6 09:25 ET · Ratings
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
newsfilter.ioAug 29 08:00 ET
Phathom Pharmaceuticals' V Oquezna: A Rising Star in GERD Treatment Market
TipRanksAug 23 12:25 ET

Comments

Jsmooth420365

Sep 4 23:20

$Phathom Pharmaceuticals (PHAT.US)$ looking PHAT!! 👌 watching for increased vol. here.

Xyno

Aug 15 09:36

$Phathom Pharmaceuticals (PHAT.US)$ breaking free of the shackles..! up she goes

TokiShadow

Aug 6 08:58

PHAT Shorts

$Phathom Pharmaceuticals (PHAT.US)$ would be nice if the shorts would just give it up already. oh well, longer time to build a bag.

Xyno

Jul 31 07:10

$Phathom Pharmaceuticals (PHAT.US)$ Lots of nervous trading going on. Once the shake out of shorters has been completed in a few weeks time and with the earnings on 8/8 this baby will go north

Iceviper

Jul 19 08:39

$Phathom Pharmaceuticals (PHAT.US)$ In a report released today, from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...